Business Description
NFL Biosciences SA
ISIN : FR0014003XT0
Compare
Compare
Traded in other countries / regions
ALNFL.France82F.Germany IPO Date
2021-07-05Description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.79 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -112.5 | |||||
| 3-Year EPS without NRI Growth Rate | -108.5 | |||||
| 3-Year Book Growth Rate | 14 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.67 | |||||
| 9-Day RSI | 24.29 | |||||
| 14-Day RSI | 29.69 | |||||
| 6-1 Month Momentum % | 186.29 | |||||
| 12-1 Month Momentum % | 1.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.7 | |||||
| Days Payable | 194.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 | |||||
| Shareholder Yield % | -0.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -362.28 | |||||
| ROA % | -94.09 | |||||
| ROIC % | -357.92 | |||||
| ROC (Joel Greenblatt) % | -94753.85 | |||||
| ROCE % | -397.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 42.33 | |||||
| Price-to-Tangible-Book | 60.67 | |||||
| EV-to-EBIT | -3.66 | |||||
| EV-to-EBITDA | -3.71 | |||||
| Price-to-Net-Current-Asset-Value | 91 | |||||
| Earnings Yield (Greenblatt) % | -27.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NFL Biosciences SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.479 | ||
| Beta | 0 | ||
| Volatility % | 113.31 | ||
| 14-Day RSI | 29.69 | ||
| 14-Day ATR (€) | 0.159891 | ||
| 20-Day SMA (€) | 2.3152 | ||
| 12-1 Month Momentum % | 1.62 | ||
| 52-Week Range (€) | 0.94 - 3.32 | ||
| Shares Outstanding (Mil) | 9.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NFL Biosciences SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NFL Biosciences SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NFL Biosciences SA Frequently Asked Questions
What is NFL Biosciences SA(XPAR:ALNFL)'s stock price today?
The current price of XPAR:ALNFL is €1.82. The 52 week high of XPAR:ALNFL is €3.32 and 52 week low is €0.94.
When is next earnings date of NFL Biosciences SA(XPAR:ALNFL)?
The next earnings date of NFL Biosciences SA(XPAR:ALNFL) is .
Does NFL Biosciences SA(XPAR:ALNFL) pay dividends? If so, how much?
NFL Biosciences SA(XPAR:ALNFL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers